鹭燕医药(002788) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥15,413,532,406.63, an increase of 7.51% compared to the same period last year[2] - Net profit attributable to shareholders decreased by 8.21% to ¥257,346,811.41[2] - Basic and diluted earnings per share both fell by 10.53% to ¥0.66[2] - Total operating revenue for the period reached ¥15,413,532,406.63, an increase of 4.3% compared to ¥14,775,163,931.09 in the previous period[13] - Net profit for the period was ¥257,901,103.73, slightly down from ¥259,059,315.29, indicating a decrease of 0.4%[14] - Earnings per share (EPS) for the period was ¥0.66, compared to ¥0.67 in the previous period[15] - The total comprehensive income for the period was ¥257,833,211.58, slightly down from ¥260,275,340.86 in the previous period[15] Cash Flow - Net cash flow from operating activities dropped significantly by 59.85% to ¥297,724,410.97[2] - Operating cash inflow for the current period reached ¥17,002,496,352.84, an increase of 1.83% from ¥16,695,347,747.84 in the previous period[16] - Net cash flow from operating activities decreased to ¥297,724,410.97, down 59.93% from ¥741,459,736.05 in the previous period[16] - Cash outflow from investment activities totaled ¥302,002,435.19, a decrease of 39.19% compared to ¥496,727,775.45 in the previous period[17] - Net cash flow from financing activities was -¥121,749,663.93, improving from -¥203,396,893.33 in the previous period[17] - The ending balance of cash and cash equivalents was ¥335,675,180.23, down from ¥445,463,828.70 in the previous period[17] - Cash received from operating activities included ¥16,773,182,605.57 from sales, up from ¥16,415,484,329.29 in the previous period[16] - Total cash outflow for operating activities was ¥16,704,771,941.87, an increase of 4.69% from ¥15,953,888,011.79 in the previous period[16] - Cash received from tax refunds was ¥1,937,751.84, an increase of 50.93% from ¥1,285,210.73 in the previous period[16] - Cash paid to employees was ¥427,648,935.85, slightly up from ¥417,505,100.09 in the previous period[16] - Cash inflow from financing activities was ¥7,100,151,424.33, an increase of 5.43% from ¥6,735,773,384.41 in the previous period[17] Assets and Liabilities - Total assets increased by 5.12% to ¥11,793,594,461.35 compared to the end of the previous year[2] - Total assets increased from 11.794 billion yuan to 12.397 billion yuan, an increase of approximately 5.1%[11] - Total liabilities rose from 8.817 billion yuan to 9.296 billion yuan, indicating an increase of about 5.4%[11] - Shareholders' equity attributable to shareholders rose by 4.27% to ¥2,946,258,377.95[2] - The total equity attributable to shareholders of the parent company increased to ¥3,072,155,028.62 from ¥2,946,258,377.95, representing a growth of 4.3%[12] - The company's total assets and equity reached ¥12,397,117,658.20 and ¥3,101,393,316.77 respectively, showing an increase from the previous year's figures[12] Investment and Expenses - Investment income for the year-to-date period decreased by 167.53% to -¥12,979,300[5] - Research and development expenses rose to ¥3,635,551.77, up from ¥2,835,211.85, marking a significant increase of 28.3%[13] - The company reported a decrease in investment income, with a loss of ¥12,979,289.94 compared to a loss of ¥4,851,615.76 in the previous period[14] - Other comprehensive income after tax was reported at -¥67,892.15, contrasting with a gain of ¥1,216,025.57 in the previous period[14] Legal and Operational Matters - The company initiated litigation against Guizhou Mingrun Construction Engineering Co., Ltd. for 39.6973 million yuan, with a court ruling awarding 31.6283 million yuan[9] - The company plans to continue pushing for the judicial auction of collateral to prioritize debt repayment[8] - The company signed new retail store lease contracts, resulting in a 46.38% increase in lease liabilities[5] - Cash flow from investing activities increased by 38.13% due to reduced expenditures on construction projects[5] - Chengdu Hechuang received a total of 7.8005 million yuan and 55.3911 million yuan from the bankruptcy estate of Guizhou Dechangxiang Pharmaceutical Co., Ltd. as part of the bankruptcy reorganization plan[8]